Supplemental Table 1 Multivariate analysis of neutrophil and platelet
|
|
- Lucinda Lewis
- 5 years ago
- Views:
Transcription
1 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 1 Multivariate analysis of neutrophil and platelet engraftment Variable Neutrophil engraftment* Platelet engraftment HR (95% CI) P value HR (95% CI) P value 0 reference 0 reference RD/1AG-MM-GVH 3.46 ( ) < ( ) <01 0 reference 0 reference RD/HLA-A-MM-GVH 4.71 ( ) < ( ) <01 RD/HLA-B-MM-GVH 2.77 ( ) < ( ) 01 RD/HLA-DR-MM-GVH 3.70 ( ) < ( ) <01 *Other significant variables in model A were; diagnosis, AML (reference, 0), ALL (HR, 1.12, 95% CI, , P = 33), CML (HR, 5, 95% CI, , P = 77, MDS (HR, 4, 95% CI, , P = 37); disease risk, standard risk (reference, 0), high risk (HR, 0.79; 95% CI, ; P < 01), status not known, (HR, 7; 95% CI, ; P = 10); year of transplantation, (reference, 0), (HR, 1.15; 95% CI, ; P = 05. Other significant variables in model A were; patient age, (reference, 0), 50- (HR, 0.72, 95% CI, 5-1, P < 01); disease risk, standard risk (reference, 0), high risk (HR, 3; 95% CI, ; P < 01), status not known, (HR, 2; 95% CI, 4-5; P = 0.122); GVHD prophylaxis, CSA/TAC + MTX (reference, 0), CSA/TAC only (HR, 6; 95% CI, ; P = 22), CSA/TAC + steroid/mmf (HR, 6; 95% CI, ; P = 0.527), other/missing (HR, 0.52; 95% CI, ; P=26). 1
2 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 2 Multivariate analysis of acute and chronic GVHD Variable grade II-IV acute GVHD* grade III-IV acute GVHD chronic GVHD extensive chronic GVHD** HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value RD/1AG-MM-GVH 1.64 ( ) < ( ) < ( ) < ( ) <01 RD/HLA-A-MM-GVH 1.52 ( ) ( ) < ( ) ( ) <01 RD/HLA-B-MM-GVH 1.79 ( ) < ( ) < ( ) < ( ) <01 RD/HLA-DR-MM-GVH 1.59 ( ) < ( ) ( ) ( ) <01 *Other significant variables; none Other significant variables in model A were; GVHD prophylaxis, CSA/TAC + MTX (reference, 0), CSA/TAC only (HR, 1.95; 95% CI, ; P < 01), CSA/TAC + steroid/mmf (HR, 1.46; 95% CI, ; P = 28), other/missing (HR, 9; 95% CI, ; P = 0.505). Other significant variables in model A were; patient age, (reference, 0), 50- (HR, 1, 95% CI, , P = 09); sex of recipient, female (reference, 0), male (HR, 1.24; 95% CI, ; P = 04); diagnosis, AML (reference, 0), ALL (HR, 0.97, 95% CI, , P = 0.736), CML (HR, 6, 95% CI, , P = 0.354), MDS (HR, 1.29, 95% CI, , P = 17); year of transplantation, (reference, 0), (HR, 0; 95% CI, ; P = 06). ** Other significant variables in model A were; sex of recipient, female (reference, 0), male (HR, 1.29; 95% CI, ; P = 16); diagnosis, AML (reference, 0), ALL (HR, 0, 95% CI, , P = 0.984), CML (HR, 1.32, 95% CI, , P = 0.176), MDS (HR, 1.49, 95% CI, , P = 07); GVHD prophylaxis, CSA/TAC + MTX (reference, 0), CSA/TAC only (HR, 0.99; 95% CI, ; P = 0.938), CSA/TAC + steroid/mmf (HR, 0.56; 95% CI, ; P = 12), other/missing (HR, 0.17; 95% CI, ; P=82) 2
3 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 3 Cause of death for patients who died without relapse Catetory RD/1AG-MM-GVH Total Graft failure 34 (5%) 2 (1%) GVHD 61 (10%) 32 (18%) IP 32 (5%) 7 (4%) Infection 235 (38%) 46 (26%) Organ failure 117 (19%) 49 (28%) Others 108 (17%) 20 (11%) Unknown 34 (5%) 19 (11%) Total Abbreviations: GVHD, graft-versus-host disease; IP, interstitial pneumonia. 3
4 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 4 Multivariate analysis of acute and chronic GVHD Variable grade II-IV acute GVHD* grade III-IV acute GVHD chronic GVHD extensive chronic GVHD** HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 0 reference 0 reference 0 reference 0 reference RD/1AG-MM-GVH wotdep 1.74 ( ) < ( ) < ( ) < ( ) <01 RD/1AG-MM-GVH wtdep 7 ( ) ( ) ( ) ( ) reference 0 reference 0 reference 0 reference RD/1AG-MM-GVH BM 1.35 ( ) ( ) < ( ) ( ) <01 RD/1AG-MM-GVH PB 1.95 ( ) < ( ) < ( ) < ( ) <01 *Other significant variables; none Other significant variables are the same as listed in Table 3, the analysis of grade III-IV acute GVHD. Other significant variables are the same as listed in Table 3, the analysis of chronic GVHD. ** Other significant variables are the same as listed in Table 3, the analysis of extensive chronic GVHD. Abbreviations: wotdep, without T cell depletion; wtdep, with T cell depletion. 4
5 Transplant using vs. HLA 1-AG mismatched RD Supplemental Table 5 Multivariate analysis of overall mortality, relapse, and non-relapse mortality Variable Overall mortality* Relapse Treatment-related mortality HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value 0 reference 0 reference 0 reference RD/1AG-MM-GVH wotdep 2 ( ) ( ) ( ) 02 RD/1AG-MM-GVH wtdep 0.71 ( 8-5 ) ( ) ( ) reference 0 reference 0 reference RD/1AG-MM-GVH BM 0.96 ( ) ( ) ( ) 29 RD/1AG-MM-GVH PB 1 ( ) ( 6-5 ) ( ) *Other significant variables are the same as listed in Table 2, the analysis of overall mortality. Other significant variables are the same as listed in Table 3, the analysis of relapse. Other significant variables are the same as listed in Table 3, the analysis of non-relapse mortality. 5
6 Transplant using vs. HLA 1-AG mismatched RD Supplemental Figure 1. Acute and chronic GVHD according to the use of T cell depletion in the RD/1AG-MM-GVH group Supplemental Figure 2. Overall survival, relapse, and non-relapse mortality according to the stem cell source in the RD/1AG-MM-GVH group 6
7 Transplant using vs. HLA 1-AG mismatched RD Supplemental Figure 1. grade II-IV acute GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep grade III-IV acute GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep Days after transplantation Days after transplantation C) D) chronic GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep extensive chronic GHVD RD/1AG-MM-GVH wotdep RD/1AG-MM-GVH wtdep
8 Transplant using vs. HLA 1-AG mismatched RD Supplemental Figure 2. Adjusted probability of overall survival relapse C) non-relapse mortality RD/1AG-MM-GVH BM RD/1AG-MM-GVH PB RD/1AG-MM-GVH BM RD/1AG-MM-GVH PB RD/1AG-MM-GVH BM RD/1AG-MM-GVH PB
Related haploidentical donors versus matched unrelated donors
Related haploidentical donors versus matched unrelated donors Bronwen Shaw, MD PhD Professor of Medicine, MCW Senior Scientific Director, CIBMTR Definition Matched Unrelated donor Refers to HLA matching
More informationASBMT. Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation
Biol Blood Marrow Transplant 19 (2013) 247e254 Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation ASBMT American Society for Blood and Marrow
More informationMUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University
MUD SCT Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University Outlines Optimal match criteria for unrelated adult donors Role of ATG in MUD-SCT Post-transplant
More informationNeutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt
Neutrophil Recovery: The First Step in Posttransplant Recovery No conflicts of interest to disclose Bus11_1.ppt Blood is Made in the Bone Marrow Blood Stem Cell Pre-B White cells B Lymphocyte T Lymphocyte
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationHaploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017
Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017 Allogeneic Transplant Recipients in the US, by Donor Type 9000
More informationSamples Available for Recipient Only. Samples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationSamples Available for Recipient and Donor
Unrelated HCT Research Sample Inventory - Summary for First Allogeneic Transplants in CRF and TED with biospecimens available through the CIBMTR Repository stratified by availability of paired samples,
More informationWhat s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016
What s new in Blood and Marrow Transplant? Saar Gill, MD PhD Jan 22, 2016 Division of Hematology-Oncology University of Pennsylvania Perelman School of Medicine 1 Who should be transplanted and how? Updates
More informationThe National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient
1988 199 1992 1994 1996 1998 2 22 24 26 28 21 212 214 216 218 Adult Donors Cord Blood Units The National Donor Program Graft Sources for Hematopoietic Cell Transplantation Dennis L. Confer, MD Chief Medical
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationEBMT Complications and Quality of Life Working Party Educational Course
EBMT Complications and Quality of Life Working Party Educational Course Organisers: R. Duarte, G. Basak 23-24 October 2014, Warsaw, Poland #EBMT2014 www.ebmt.org EBMT Complications and Quality of Life
More informationAn Introduction to Bone Marrow Transplant
Introduction to Blood Cancers An Introduction to Bone Marrow Transplant Rushang Patel, MD, PhD, FACP Florida Hospital Medical Group S My RBC Plt Gran Polycythemia Vera Essential Thrombocythemia AML, CML,
More informationMUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK
MUD HSCT as first line Treatment in Idiopathic SAA Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK No Financial Disclosures Guidelines for management of aplastic anaemia British
More informationRob Wynn RMCH & University of Manchester, UK. HCT in Children
Rob Wynn RMCH & University of Manchester, UK HCT in Children Summary Indications for HCT in children Donor selection for Paediatric HCT Using cords Achieving engraftment in HCT Conditioning Immune action
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationWhat s a Transplant? What s not?
What s a Transplant? What s not? How to report the difference? Daniel Weisdorf MD University of Minnesota Anti-cancer effects of BMT or PBSCT [HSCT] Kill the cancer Save the patient Restore immunocompetence
More informationHaploidentical Transplantation today: and the alternatives
Haploidentical Transplantation today: and the alternatives Daniel Weisdorf MD University of Minnesota February, 2013 No matched sib: where to look? URD donor requires close HLA matching and 3-12 weeks
More information5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow
5/9/2018 or Stem Cell Harvest Where we are now, and What s Coming AA MDS International Foundation Indianapolis IN Luke Akard MD May 19, 2018 Infusion Transplant Conditioning Treatment 2-7 days STEM CELL
More informationHaplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
More informationSetting The setting was secondary care. The economic analysis was carried out in Canada.
Allogeneic stem cell transplantation: an economic comparison of bone marrow, peripheral blood, and cord blood technologies Jacobs P, Hailey D, Turner R, MacLean N Record Status This is a critical abstract
More informationAcknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center
The Addition of Extracorporeal Photopheresis (ECP) to Tacrolimus and Methotrexate to Prevent Acute and Chronic Graft- Versus Host Disease in Myeloablative Hematopoietic Cell Transplant (HCT) Anthony Accurso,
More informationOutcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched. unrelated donors
Outcomes of pediatric bone marrow transplantation for leukemia and myelodysplasia using matched sibling, mismatched related or matched unrelated donors Immunobiology Working Committee PIs: Peter Shaw and
More information3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)
3 Results 3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25) Five infusions of monoclonal IL-2 receptor antibody (anti-cd25) were planned according to protocol between day 0 and day
More informationOne Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases
One Day BMT Course by Thai Society of Hematology Management of Graft Failure and Relapsed Diseases Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital
More informationHee-Je Kim, Woo-Sung Min, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok Lee, Seok-Goo Cho, Jong-Youl Jin, Jong-Wook Lee, Chun-Choo Kim
Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia Hee-Je
More informationRole of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT
Role of NMDP Repository in the Evolution of HLA Matching and Typing for Unrelated Donor HCT Stephen Spellman, MBS Director, Immunobiology and Observational Research Assistant Scientific Director CIBMTR,
More informationHLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia
BRIEF COMMUNICATION HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia Shang-Ju Wu, Ming Yao,* Jih-Luh Tang, Bo-Sheng Ko, Hwei-Fang
More informationDonatore HLA identico di anni o MUD giovane?
Donatore HLA identico di 60-70 anni o MUD giovane? Stella Santarone Dipartimento di Ematologia, Medicina Trasfusionale e Biotecnologie Pescara AGENDA 1. Stem Cell Donation: fatalities and severe events
More informationThe question is not whether or not to deplete T-cells, but how to deplete which T-cells
The question is not whether or not to deplete T-cells, but how to deplete which T-cells CD34+ positive selection Negative Depletion of: CD3/CD19 TcRαβ/CD19 T-cell depletion: positive selection versus negative
More informationTrends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014
Trends in Hematopoietic Cell Transplantation AAMAC Patient Education Day Oct 2014 Objectives Review the principles behind allogeneic stem cell transplantation Outline the process of transplant, some of
More informationAbstract. Introduction. Editor: M. Paul
ORIGINAL ARTICLE MYCOLOGY Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation
More informationCHAPTER 2 PROTOCOL DESIGN
CHAPTER 2 PROTOCOL DESIGN CHAPTER 2 PROTOCOL DESIGN 2.1 ELIGIBILITY CRITERIA Participants fulfilling the following criteria will be eligible for enrollment in the protocol: 1. Participant is diagnosed
More informationMATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH
MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH TEJASWINI M. DHAWALE, M.D. HEME FELLOWS CONFERENCE NOVEMBER 08, 2013 CASE PRESENTATION 51 yo M with history of MDS (unilinear
More informationReduced-intensity Conditioning Transplantation
Reduced-intensity Conditioning Transplantation Current Role and Future Prospect He Huang M.D., Ph.D. Bone Marrow Transplantation Center The First Affiliated Hospital Zhejiang University School of Medicine,
More informationCONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints
CONSIDERATIONS IN DESIGNING ACUTE GVHD PREVENTION TRIALS: Patient Selection, Concomitant Treatments, Selecting and Assessing Endpoints CENTER FOR INTERNATIONAL BLOOD AND MARROW TRANSPLANT RESEARCH Potential
More informationTransplant Booklet D Page 1
Booklet D Pretest Correct Answers 4. (A) is correct. Technically, performing a hematopoietic stem cell transplant is one of the simplest transplantation procedures. The hematopoietic stem cells are infused
More informationCurrent Status of Haploidentical Hematopoietic Stem Cell Transplantation
Current Status of Haploidentical Hematopoietic Stem Cell Transplantation Annalisa Ruggeri, MD, PhD Hematology and BMT Unit Hôpital Saint Antoine, Paris, France #EBMTITC16 www.ebmt.org Hematopoietic SCT
More informationHaploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy
Haploidentical Transplants for Lymphoma Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy HODGKIN NON HODGKIN Non Myelo Ablative Regimen Luznik L et al BBMT 2008 Comparison of Outcomes
More informationReview of Aplastic Anemia Guidelines. Seiji Kojima MD. PhD.
Review of Aplastic Anemia Guidelines Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific Blood
More informationEffect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation
Version 3-30-2009 Effect of Conditioning Regimen Intensity on CMV Infection in Allogeneic Hematopoietic Cell Transplantation Authors: Hirohisa Nakamae, 1 Katharine A. Kirby, 1 Brenda M. Sandmaier, 1,2
More informationBack to the Future: The Resurgence of Bone Marrow??
Back to the Future: The Resurgence of Bone Marrow?? Thomas Spitzer, MD Director. Bone Marrow Transplant Program Massachusetts General Hospital Professor of Medicine, Harvard Medical School Bone Marrow
More informationThe role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
More informationFactors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection
Factors Influencing Haematopoietic Progenitor cell transplant outcome Optimising donor selection Alison Logan Transplantation Laboratory Manchester Royal Infirmary Haematopoietic progenitor cell transplants
More informationBone Marrow Transplantation in Myelodysplastic Syndromes. An overview for the Myelodysplasia Support Group of Ottawa
Bone Marrow Transplantation in Myelodysplastic Syndromes An overview for the Myelodysplasia Support Group of Ottawa Objectives Provide brief review of marrow failure Re emphasize the importance of predictions
More informationThe future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD
The future of HSCT John Barrett, MD, NHBLI, NIH Bethesda MD Transplants today Current approaches to improve SCT outcome Optimize stem cell dose and source BMT? PBSCT? Adjusting post transplant I/S to minimize
More informationTransplantation - Challenges for the future. Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust
Transplantation - Challenges for the future Dr Gordon Cook S t James s Institute of Oncology, Leeds Teaching Hospitals Trust Bone Marrow Transplantation Timeline, 1957-2006 Appelbaum F. N Engl J Med 2007;357:1472-1475
More informationNiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials
NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute Adult Umbilical Cord Blood Transplantation
More informationStem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
More informationEffect of HLA mismatch on acute graft-versus-host disease
Int J Hematol (2013) 98:300 308 DOI 10.1007/s12185-013-1405-x PROGRESS IN HEMATOLOGY New clinical and basic aspects of graft-versus-host disease Effect of HLA mismatch on acute graft-versus-host disease
More informationDisclosures. Investigator-initiated study funded by Astellas
Disclosures Investigator-initiated study funded by Astellas 1 Background Widespread use of preemptive therapy strategies has decreased CMV end-organ disease to 5-8% after HCT. Implications for development
More informationStem Cell Transplantation
Stem Cell Transplantation Evelyne Willems Centre Hospitalier Universitaire, ULg, Liège Post-ASH meeting, January 11, 2012, Brussels Plan 1. Select the patient: validation of HCT-CI 2. Select the donor
More informationHAEMATOPOIETIC STEM CELL TRANSPLANTATION
PRIMARY IMMUNODEFICIENCIES HAEMATOPOIETIC STEM CELL TRANSPLANTATION HAEMATOPOIETIC STEM CELL TRANSPLANTATION 1 PRIMARY IMMUNODEFICIENCIES KEY ABBREVIATIONS CID GvHD HSCT IPOPI PID SCID BMT HSC Combined
More informationTransplantation with unrelated bone marrow in leukaemic patients above 40 years of age
Bone Marrow Transplantation, (1998) 21, 43 49 1998 Stockton Press All rights reserved 0268 3369/98 $12.00 Transplantation with unrelated bone marrow in leukaemic patients above 40 years of age O Ringdén
More informationBone Marrow Transplantation and the Potential Role of Iomab-B
Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1 Hematopoietic Cell Transplantation
More informationUse of alternative donors in HSCT (Europe)
Use of alternative donors in HSCT (Europe) Passweg JR, Baldomero H, Bader P et al (2015) Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors
More informationSummary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
More informationUMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT
UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT Mitchell E. Horwitz, MD Duke University Medical Center Duke Cancer Institute
More informationNothing to disclose. Title of the presentation - Author
Nothing to disclose Title of the presentation - Author 1 www.ebmt.org Complications after HSCT Alicia Rovó MD London 9/04/2013 Introduction Risk factors for transplant complication Type of complications
More informationAcute GVHD. ESH-EBMT 2009 Latimer A. Devergie
Acute GVHD ESH-EBMT 2009 Latimer A. Devergie Acute GVHD Activated Donor T cells damage host epithelial cells after an inflammatory cascade that begins after the preparative regimen GVHD is the major barrier
More informationStem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital
Stem cell transplantation for haemoglobinopathies Dr P J Darbyshire Birmingham Childrens Hospital Survival by Cohort of Birth (N=977) 1.00 85-97 80-84 75-79 70-74 0.75 Survival Probability 0.50 0.25 P
More informationAbstract. Introduction
ORIGINAL ARTICLE MYCOLOGY The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion Y.-Q. Sun, L.-P. Xu,
More informationUKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )
Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg)
More informationDr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
More informationRBC Transfusion
RBC Transfusion 2014년혈액종양내과춘계연수강좌 Won SikLee, M.D., Ph.D. Division of Hemato-Oncology, Department of Internal Medicine, Inje University College of Medicine, Busan Paik Hospital 2014. 06. 21. Background
More informationStem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT
Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation
More informationUnderstanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
More informationIs in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation. Disclosure of Interest: Nothing to Disclose
Rupert Handgretinger Children s University Hospital, Tübingen, Germany Is in vitro T-cell depletion necessary for Haploidentical TransplantationTitle of Presentation Disclosure of Interest: Nothing to
More informationT-cell Exhaustion in Leukemia Relapse Post Allogeneic Stem Cell Transplantation
T-cell Exhaustion in Leukemia Relapse Post Allogeneic Stem Cell Transplantation Hong Zheng, M.D., Ph.D. Assistant Professor of Medicine Penn State Hershey Cancer Institute Penn State University College
More informationIntroduction to Hematopoietic Stem Cell Transplantation
Faculty Disclosures Introduction to Hematopoietic Stem Cell Transplantation Nothing to disclose Jeanne McCarthy-Kaiser, PharmD, BCOP Clinical Pharmacist, Autologous Stem Cell Transplant/Long- Term Follow-Up
More informationCover Page. The handle holds various files of this Leiden University dissertation.
Cover Page The handle http://hdl.handle.net/1887/20898 holds various files of this Leiden University dissertation. Author: Jöris, Monique Maria Title: Challenges in unrelated hematopoietic stem cell transplantation.
More informationDedicated to Gordon. Stem Cell Transplantation: The Journey
Dedicated to Gordon Stem Cell Transplantation: The Journey 1949 Jacobson et al: Radioprotection by lead shielding of the spleen of a lethally irradiated animal 1951 Lorenz et al: Radiation protection
More informationAllogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade ( )
TRANSPLANTATION Allogeneic hematopoietic stem cell transplantation from family members other than -identical siblings over the last decade (1991-2000) Yoshinobu Kanda, Shigeru Chiba, Hisamaru Hirai, Hisashi
More informationCorrespondence should be addressed to Yingjun Chang;
Hindawi Immunology Research Volume 2017, Article ID 1043836, 8 pages https://doi.org/10.1155/2017/1043836 Research Article Donor-Specific Anti-Human Leukocyte Antigen Antibodies Predict Prolonged Isolated
More informationRegression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome
MOLECULAR AND CLINICAL ONCOLOGY 2: 81-86, 2014 Regression of eosinophil counts after diagnosis of chronic graft-versus-host disease as a potential marker for improved clinical outcome FABIAN BEIER 1, KLAUS
More informationExperience of patients transplanted with naïve T cell depleted stem cell graft in CMUH
Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH Tzu-Ting Chen, Wen-Jyi Lo, Chiao-Lin Lin, Ching-Chan Lin, Li-Yuan Bai, Supeng Yeh, Chang-Fang Chiu Hematology and
More informationRIC in Allogeneic Stem Cell Transplantation
RIC in Allogeneic Stem Cell Transplantation Rainer Storb, MD Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine Seattle, WA Disclosure Grant Support: NIH grants
More informationT cell manipulation of the graft: Yes
T cell manipulation of the graft: Yes J.H. Frederik Falkenburg Department of Hematology L M U C Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for non-malignant disorders: no need for anti-tumor
More informationIntroduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018
Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018 The transfer of hematopoietic progenitor and stem cells for therapeutic purposes Hematopoietic Cell
More informationAllogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD
Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD Overview: Update on allogeneic transplantation for malignant and nonmalignant diseases: state
More informationKEY WORDS: Unrelated SCT, HLA-mismatch, ATG, Graft-versus-host disease
HLA-Mismatched Unrelated Donors as an Alternative Graft Source for Allogeneic Stem Cell Transplantation after Antithymocyte Globulin-Containing Conditioning Regimen Nicolaus Kröger, 1 Tatjana Zabelina,
More informationIncreasing numbers of patients are receiving reduced intensity conditioning regimen
ARTICLE Stem Cell Transplantation EUROPEAN HEMATOLOGY ASSOCIATION Haematologica 2016 Volume 101(2):256-262 Correspondence: Bipin.Savani@Vanderbilt.Edu Received: 22/08/2015. Accepted: 10/11/2015. Pre-published:
More informationThe impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children
VOLUME 46 ㆍ NUMBER ㆍ March 0 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE The impact of HLA matching on unrelated donor hematopoietic stem cell transplantation in Korean children Meerim Park, Kyung
More informationAn Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
More informationTherapeutic Advances in Treatment of Aplastic Anemia. Seiji Kojima MD. PhD.
Therapeutic Advances in Treatment of Aplastic Anemia Seiji Kojima MD. PhD. Department of Pediatrics Nagoya University Graduate School of Medicine Chairman of the Severe Aplastic Anemia Working Party Asia-Pacific
More informationCarol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT
Carol Cantwell Blood Transfusion Laboratory Manager St Mary s Hospital, ICHNT History Why is blood transfusion involved? What tests are performed in blood transfusion and why? What does a protocol look
More informationWorkshop I: Patient Selection Current indication for HCT in adults. Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan
Workshop I: Patient Selection Current indication for HCT in adults Shinichiro Okamoto MD, PhD Keio University, Tokyo, Japan Factors to Take into Account with Recommending HCT Patient & disease factors
More informationHaploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia
Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia Carmem Bonfim Director Pediatric Blood and Marrow Transplantation Program HC Federal
More informationNIH Public Access Author Manuscript Lancet Oncol. Author manuscript; available in PMC 2011 August 29.
NIH Public Access Author Manuscript Published in final edited form as: Lancet Oncol. 2010 July ; 11(7): 653 660. doi:10.1016/s1470-2045(10)70127-3. Effect of Graft Source on Unrelated Donor Haemopoietic
More informationAcute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University
Acute Graft-versus-Host Disease (agvhd) Udomsak Bunworasate Chulalongkorn University Graft-versus-Host Disease (GVHD) Background GVHD is an immunologic reaction of the donor immune cells (Graft) against
More information25/10/2017. Clinical Relevance of the HLA System in Blood Transfusion. Outline of talk. Major Histocompatibility Complex
Clinical Relevance of the HLA System in Blood Transfusion Dr Colin J Brown PhD FRCPath. October 2017 Outline of talk HLA genes, structure and function HLA and immune complications of transfusion TA-GVHD
More informationBusulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate
Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate Donald Hutcherson, RPh Clinical Pharmacy Specialist BMT Emory University Hospital/Winship Cancer Institute
More informationA CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES
Chinese Journal of Cancer Research 9(1):36--40,1997, Clinical Observations A CLINICAL STUDY OF THE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN 112 PATIENTS WITH LEUKEMIA AND OTHER MALIGNANT DISEASES Liu
More informationReduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts
Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts Yi-Bin Chen, 1 Julie Aldridge, 2 Haesook T. Kim, 2 Karen K. Ballen, 1 Corey
More informationDoes NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia
Does NK cell alloreactivity prevent relapse? Yes!!! Andrea Velardi Bone Marrow Transplant Program University of Perugia Recognition of missing self HLA triggers lysis NK Inhibitory receptor Activating
More informationKEY WORDS: Total body irradiation, acute myelogenous leukemia, relapse
The Addition of 400 cgy Total Body Irradiation to a Regimen Incorporating Once-Daily Intravenous Busulfan, Fludarabine, and Antithymocyte Globulin Reduces Relapse Without Affecting Nonrelapse Mortality
More informationOneMatch Stem Cell and Marrow Network. Training Guide
OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save
More informationISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection
ISCT Workshop #7 Perspectives in Cell Selection Immunomagnetic Selection Carolyn A. Keever-Taylor, PhD Medical College of Wisconsin June 7, 2012 History of Available Devices CellPro CEPRATE Avidin/Biotin
More informationMulti-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant
Multi-Virus-Specific T cell Therapy for Patients after HSC and CB Transplant Hanley PJ, Krance BR, Brenner MK, Leen AM, Rooney CM, Heslop HE, Shpall EJ, Bollard CM Hematopoietic Stem Cell Transplantation
More informationScoring HLA Class I Mismatches by HistoCheck Does Not Predict Clinical Outcome in Unrelated Hematopoietic Stem Cell Transplantation
Scoring HLA Class I Mismatches by HistoCheck Does Not Predict Clinical Outcome in Unrelated Hematopoietic Stem Cell Transplantation Stephen Spellman, 1 John Klein, 2 Michael Haagenson, 1 Medhat Askar,
More information